POZ - Treatment News : GSK Halts PI Brecanavir - by Tim Horn
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2006

Web Exclusives

Evaluating the Costs of Earlier HIV Treatment

HIV Prevention Gets “Fergalicious”

Changing the HIV Treatment Paradigm

» More

Most Talked About

Magic Johnson Accused of Faking HIV (41)

The POZ/DDF Ratio (blog) (30)

Guidelines Prediction: Start Treatment Earlier (blog) (16)

HIV-Positive People Living Longer Than Ever Before (14)

Bone Marrow Transplant: Potential AIDS Cure? (8)

Obama Campaign Set to Boost Domestic HIV/AIDS Funding (8)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

December 18, 2006

GSK Halts PI Brecanavir
(AIDSmeds.com)

by Tim Horn

(AIDSmeds.com)—GlaxoSmithKline (GSK) announced on December 18 that it has discontinued development of brecanavir, its experimental protease inhibitor, due to “insurmountable” problems developing a formulation for the drug.

Early studies, including a 24-week Phase II study, indicated that brecanavir held promise for HIV-positive people either starting therapy for the first time or those with virus resistant to other protease inhibitors.

According to press release issued by GSK, the decision to halt development of brecanavir was based on the company’s inability to develop a viable oral dosage formulation capable of delivering the desired drug levels in treatment-experienced patients.

“As in all of our drug development programs," the press release said, "GSK investigated several formulations of brecanavir. We conducted extensive studies in an effort to identify a formulation that would maximize therapeutic benefit for people living with HIV, especially those who are heavily treatment-experienced. Ultimately, our formulation work could not overcome the limitations of the brecanavir molecule which make consistent delivery of target drug levels unachievable.”

GSK is in the process of notifying researchers associated with clinical trials of brecanavir. HIV-positive patients receiving brecanavir through these studies will be taken off the drug and directed to an approved HIV option or another experimental agent, if necessary.

emailrssprint


[Go to top]


Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Would legalizing prostitution reduce the spread of HIV?
Yes
No
I don't know.

Monthly Poll
Question: Do you believe that prisoners receive adequate health care?
Yes
No
I don't know.

Surveys
Tell us when and to whom you disclose your status.

Tell us about your travel experiences.

more surveys
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy